Many of the most advanced scientific technologies in regenerative medicine involve animal or human embryonic stem cells.
Together with the scientific community, we believe that research using stem cells has the potential to help identify medicines, therapies and vaccines that will treat, cure or prevent diseases, and alleviate the suffering of patients with significant, unmet medical needs. Examples include neurodegenerative diseases, cancer, cardiovascular disease, diabetes, osteoarthritis, infectious diseases and trauma.
For more than a decade, we have been applying advances made in stem-cell technologies to support our research and development. The capacity of stem cells to differentiate into specific cell types underscores their versatility and utility, from early target validation and identification, to screening and testing of potential new therapeutics, disease-modeling, generating humanized-animal models and pre-clinical proof of concept. Recent advances in 3-D cell culture systems and gene-editing technologies have further increased the potential impact of stem cells in the development of new medicines.
We conduct research using stem cells in full accordance with all applicable laws and regulations, and our own internal research policies. Our research policy involving stem cells adheres to the U.S. National Academy of Sciences guidelines as well as those of the International Society of Stem Cell Research. Our company’s Regenerative Medicine Oversight Committee, which comprises both internal and external experts, oversees company-sponsored research involving stem cells, including highly targeted research using human embryonic stem cells and induced pluripotent stem cells. The committee is responsible for ensuring that all projects involving stem cells adhere to our policies.